DR.AGARWALS EYE HOSPITAL LTD.-$ (DRAGARWQ) Fair Value & Analysis
Healthcare · IN · Market cap ₹24.3B
Fair value as of: Aug 13, 2026
From 24 valuation models · updated 6 days ago
Fair value updated Aug 13, 2026, revised from ₹2,901 to ₹3,191 (+10.0%) since Aug 12, 2026.
A solid business, but screening 40% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (₹3,989). The favourable scenario is already priced in.
- The model range is unusually wide (₹1,509 to ₹3,989). The outcome hinges heavily on assumptions, so read the point estimate with caution.
- Solid but not exceptional quality (54/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range ₹302.95 – ₹6,972 · fair‑value band ₹1,509 – ₹3,989 · the ₹5,316 price screens above the ₹3,191 fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
DR.AGARWALS EYE HOSPITAL LTD.-$ (DRAGARWQ) currently trades at ₹5,316, while our model-based Fair Value estimate is ₹3,191, implying the stock looks roughly 40.0% overvalued today. The Quality Score stands at 54/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, DR.AGARWALS EYE HOSPITAL LTD.-$ generated revenue of ₹4.7B at a net margin of 14.9%. Revenue grew 20.2% year over year. It earns a return on equity of 25.2%. Net debt stands at ₹752M. Fundamentals as of Aug 13, 2026
Our scenario range runs from ₹1,509 (bear case) to ₹3,989 (bull case); at ₹5,316, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 17% below its 52-week high and 26% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -31% fair-value upside, at -40%, DRAGARWQ screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: Growth Earnings (₹4,073) versus Asset-Based (₹480.09). Highest evidence: Growth DCF (80).
Notify me when DRAGARWQ reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 55 · Market factors (momentum, volatility) 61
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Dr. Agarwal's Eye Hospital Limited engages in the provision of eye care and related services in India, Ghana, Uganda, Kenya, Madagascar, Tanzania, Rwanda, Zambia, Mozambique, and Mauritius.
Full company description
Dr. Agarwal's Eye Hospital Limited engages in the provision of eye care and related services in India, Ghana, Uganda, Kenya, Madagascar, Tanzania, Rwanda, Zambia, Mozambique, and Mauritius. The company, through its hospitals, offers services in the areas of cataract, glaucoma, laser correction, cornea and refractive, retina, squint, keratitis, diabetic retinopathy, retinal detachment, nystagmus, ptosis, conjunctivitis, retinopathy prematurity, macular hole and edema, cornea transplantation, behcets, computer vision syndrome, hypertensive retinopathy, black fungus, traumatic cataract, keratoconus, uveitis, pterygium, blepharitis, posterior subcapsular cataract, rosette cataract, and congenital glaucoma. Dr. Agarwal's Eye Hospital Limited was founded in 1957 and is based in Chennai, India. Dr. Agarwal's Eye Hospital Limited operates as a subsidiary of Dr. Agarwal's Health Care Limited.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
DR.AGARWALS EYE HOSPITAL LTD.-$ reported revenue of ₹4.7B in FY2026 versus ₹2.0B in FY2022, a compound +23.7%/yr. Reported net income was ₹701M in FY2026, compounding +30.6%/yr from FY2022.
DRAGARWQ screens 40% overvalued. Compare with HCA Healthcare, Inc →
Peer Group
Medical Care Facilities · 270 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Care Facilities median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc HCA | $414.59 | $547.67 | +32% |
| Fresenius SE FRE | €46.82 | €32.15 | -31% |
| Dr. Sulaiman Al Habib Medical Services Group 4013 | 235.00 SAR | 112.37 SAR | -52% |
| IHH Healthcare Berhad, an investment holding company, Q0F | 2.67 SGD | 1.44 SGD | -46% |
| Rede D'Or São Luiz S.A RDOR3 | R$33.09 | R$47.31 | +43% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,818 | ₹2,955 | -66% |
| Aier Eye Hospital Group 300015 | ¥8.87 | ¥7.67 | -14% |
| Max Healthcare Institute Limited MAXHEALTH | ₹1,008 | ₹284.87 | -72% |
| Bangkok Dusit Medical Services Public Company BDMS | 19.40 THB | 18.57 THB | -4% |
| Fortis Healthcare Limited FORTIS | ₹906.15 | ₹300.29 | -67% |
Compare DR.AGARWALS EYE HOSPITAL LTD.-$ with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is DR.AGARWALS EYE HOSPITAL LTD.-$ (DRAGARWQ) overvalued or undervalued?
What is the fair value of DRAGARWQ?
What is the quality score of DRAGARWQ?
What is the revenue of DR.AGARWALS EYE HOSPITAL LTD.-$ (DRAGARWQ)?
What is the net profit margin of DRAGARWQ?
Does DR.AGARWALS EYE HOSPITAL LTD.-$ pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track DR.AGARWALS EYE HOSPITAL LTD.-$ and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.